Acadia Pharmaceuticals (ACAD) Stock News

Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to 26 new employees under its 2024 Inducement Plan, as approved by the Compensation Committee. The awards include 63,477 non-qualified stock options at an exercise price of $23.64 per share and 49,377 restricted stock units (RSUs).

The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting at the second anniversary and the remaining 50% in two equal annual installments. All awards are subject to continued employment with Acadia.

Acadia is known for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome in the US and Canada. The company continues to focus on neuroscience and neuro-rare diseases, including programs for Prader-Willi syndrome and Alzheimer's disease psychosis.

Acadia Pharmaceuticals (Nasdaq: ACAD) reported strong Q2 2025 financial results with total revenues of $264.6 million, up 9% year-over-year. The company's two key products showed solid growth: NUPLAZID sales increased 7% to $168.5 million, while DAYBUE sales grew 14% to $96.1 million.

The company reported net income of $26.7 million ($0.16 per share) and raised its NUPLAZID 2025 sales guidance to $665-690 million. Acadia maintained strong cash position of $762 million and expects top-line results from its COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome in early Q4 2025.

Notable achievements include patent litigation wins securing NUPLAZID market exclusivity until 2038 and reaching a record high of 987 unique DAYBUE patients in Q2.

Acadia Pharmaceuticals (Nasdaq: ACAD) announced its participation in the Canaccord Genuity 45th Annual Growth Conference, scheduled for August 13, 2025, at 2:30 p.m. Eastern Time. The company will engage in a fireside chat that will be accessible via webcast on Acadia.com's investor section.

Acadia is notable for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome in the US and Canada. The company's pipeline includes clinical-stage programs focusing on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuroscience and neuro-rare diseases.

Acadia Pharmaceuticals (Nasdaq: ACAD) has appointed Scott Cenci as Senior Vice President, Chief Information and Data Officer. Cenci, who will report to CEO Catherine Owen Adams, brings over 25 years of experience in pharmaceutical and biotechnology industries.

In his previous role at Genmab, Cenci led the transformation of IT operations, supporting the company's growth from 500 to 2,700 employees and revenue expansion from $750 million to over $3 billion. His extensive experience includes leadership positions at Biogen, Zoetis, and Pfizer, where he specialized in digital transformation, AI initiatives, and global IT operations.

Acadia Pharmaceuticals (NASDAQ: ACAD) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.

Acadia is a biopharmaceutical company focused on neurological and rare diseases, notably known for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome in the U.S. and Canada. Their pipeline includes clinical-stage programs targeting Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuroscience and neuro-rare diseases.

Acadia Pharmaceuticals (NASDAQ: ACAD) has granted inducement awards to seventeen new employees under its 2024 Inducement Plan. The awards include 35,607 non-qualified stock options at an exercise price of $21.24 per share and 29,571 restricted stock units (RSUs).

The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting after two years and the remaining 50% in two equal annual installments. Both awards are subject to continued employment.

Acadia is known for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome, with ongoing clinical-stage development focused on Prader-Willi syndrome and Alzheimer's disease psychosis.

Acadia Pharmaceuticals (NASDAQ:ACAD) hosted its inaugural R&D Day to showcase its pipeline programs and growth strategy. The company plans to initiate seven Phase 2 or Phase 3 studies during 2025-2026, with five key readouts anticipated by 2027.

Key pipeline highlights include ACP-101 for Prader-Willi syndrome, ACP-204 for Alzheimer's and Lewy Body Dementia Psychosis, ACP-211 for major depressive disorder, ACP-711 for Essential Tremor, and ACP-271 for Tardive Dyskinesia and Huntington's Disease. The company's commercial franchises are expected to generate over $1 billion in net sales this year.

Acadia Pharmaceuticals announced inducement grants to 41 new employees under its 2024 Inducement Plan, approved by the Compensation Committee on June 6, 2025. The grants include non-qualified stock options to purchase 187,664 shares at $21.98 per share and 89,582 restricted stock units (RSUs). The stock options will vest over 4 years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest over 4 years, with 50% vesting at the second anniversary and the remaining in two annual installments. Acadia, known for developing the first FDA-approved drug for Parkinson's disease psychosis hallucinations and Rett syndrome treatment, continues to focus on neuroscience breakthroughs, with ongoing clinical trials in Prader-Willi syndrome and Alzheimer's disease psychosis.

The U.S. Court of Appeals for the Federal Circuit has affirmed a Delaware District Court ruling validating Acadia Pharmaceuticals' NUPLAZID (pimavanserin) '740 composition of matter patent, securing protection until 2030. This decision follows a recent favorable ruling for Acadia's formulation patent, which extends protection for the NUPLAZID 34 mg capsule formulation until 2038. The court's decision came in litigation against MSN Laboratories and builds on the precedent from Allergan USA v. MSN Laboratories case. NUPLAZID is notable as the first FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company is also advancing clinical-stage development programs for Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuroscience and neuro-rare diseases.